Clinical trials: Headache Disorder
Migraine
Study Designed to Evaluate the Safety of Prophylactic Depakote ER in the Treatment of Adolescents With Migraine
The purpose of this study is to determine if long-term treatment, up to 1 year, with Depakote ER is safe in the reduction of occurrence of migraine headaches in adolescents.
- Trial name
- NCT00195806
- Testing
- divalproex sodium
- Where
- United States
- Volunteers
- 315 people
- Sponsor
- Abbott
Migraine
Evaluation of Treatment Satisfaction and Preference for Sumavel DosePro in the Treatment of Migraine
The purpose of the study is to evaluate the treatment satisfaction of subjects using Sumavel DosePro to treat their moderate to severe migraines.
- Trial name
- NCT01016834
- Testing
- Sumavel DosePro, Sumatriptan
- Where
- 21 sites in United States
- Volunteers
- 246 people
- Sponsor
- Zogenix, Inc.
Chronic Migraine
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine
Migraine is characterized by attacks of throbbing, moderate or severe headache, often associated with nausea, vomiting, and/or sensitivity to light and/or sound.
- Trial name
- ATO-BOTOX (NCT05216263)
- Testing
- Atogepant
- Where
- 29 sites in United States
- Volunteers
- 75 people
- Sponsor
- AbbVie
Headache, Migraine
Erenumab (AMG 334) Plus Combined Oral Contraceptive Drug Interaction Study in Healthy Females
A pharmacokinetic drug interaction study of erenumab and an oral contraceptive containing progestin and estrogen.
- Trial name
- NCT02792517
- Testing
- Erenumab, Ethynil Estradiol/Norgestimate Oral Contraceptive
- Where
- 4 sites in United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Amgen
Migraine
Single Ascending Dose Study to Investigate the Safety and Pharmacokinetics of XC101-D13H in Healthy Adult Subjects
This is a randomized, double-blind, placebo-controlled, parallel-group single ascending dose (SAD) study. There are 4 cohorts of 8 subjects (8 active and 2 placebo) planned for evaluation under fasting conditions.
- Trial name
- NCT04104399
- Testing
- XC101-D13H
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Xoc Pharmaceuticals
Migraine, Acute
Use Of SB-705498 In The Acute Treatment Of Migraine
Despite the success of the triptan class of drugs, approximately 60% of patients who take medication at the moderate to severe pain stage of acute migraine, still have pain of mild or greater degree at 2 hrs post dose.
- Trial name
- NCT00269022
- Testing
- SB-705498
- Where
- 4 sites in Australia, Canada and 2 more
- Volunteers
- 70 people
- Sponsor
- GlaxoSmithKline
Migraine Headache, Cognitive Impairment
Treximet in Acute Migraine Headache: Assessing Cognitive Function
Migraine headache occurs frequently in women more than men and is associated with symptoms not only of significant pain but also of symptoms typically including of photophobia, phonophobia, nausea and vomiting.
- Trial name
- NCT00837044
- Testing
- Treximet, Migraine rescue medication of choice
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Neurological Research Center
Primary Headache Disorders
A Prospective Observational Registry of Primary Headache Patients Treated With Ausanil
This study is an observational study with the primary objective to assess the safety and tolerability of Ausanil in the treatment of primary headache disorders.
- Trial name
- NCT02392273
- Testing
- Ausanil
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- VR1 Corporation
Headache, Nausea
Evaluation of a Fixed Combination of Herbal Extracts to Prevent Symptoms Alcohol-induced Hangovers
The primary objective of the study is to test whether the tested Product LACIME Anti-hangover is effective in preventing the signs and symptoms of alcohol-induced hangover (such as headache, impaired memory, depression, anxiety…
- Conditions
- Headache, Nausea, Dizziness, Sleepiness
- Trial name
- LACIME (NCT04183842)
- Testing
- LACIME Anti-hangover
- Where
- Armenia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Incara Lab
Migraine
Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman
The purpose of this study is to determine the safety, tolerability and pharmacokinetics of ALD1910, a monoclonal antibody, administered by intravenous infusion and subcutaneous injection.
- Trial name
- NCT04197349
- Testing
- ALD1910, Sumatriptan
- Where
- Australia
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Migraine Headaches
The Safety Of Combo Formulation In The Treatment Of Multiple Episodes Of Acute Migraine Over 12 Months
The objective of this study is to assess the safety of a single-tablet dose of Combo Formulation for the treatment of moderate to severe migraines
- Trial name
- NCT00442221
- Testing
- Sumatriptan and Naproxen sodium
- Where
- 2 sites in United States
- Volunteers
- 500 people
- Sponsor
- POZEN
Migraine
Study to Assess Effectiveness of Oral Atogepant in Adult Participants For Prevention of Migraine in the United Kingdom
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound.
- Trial name
- PRACTICE (NCT07690215)
- Volunteers
- 200 people
- Sponsor
- AbbVie
Migraine
Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine
The primary objective of this study is to evaluate the treatment benefit of erenumab on headache duration of at least moderate pain intensity.
- Trial name
- EMBRACE (NCT04252742)
- Testing
- Erenumab
- Where
- 91 sites in United States, Bulgaria and 7 more
- Volunteers
- 512 people
- Sponsor
- Amgen
Resistant Migraine, Chronic Migraine Headache
A Pivotal Clinical Study to Evaluate the MySalvia System for the Treatment of Resistant Migraine
The purpose of this pivotal clinical study is to evaluate the safety and effectiveness of the MySalvia System, a minimally invasive implantable neuromodulation therapy, for the preventive treatment of adults with resistant…
- Conditions
- Resistant Migraine, Chronic Migraine Headache, Headache (Migraine), Headache, Cluster
- Trial name
- RECLAIM-II (NCT07719608)
- Testing
- Neurostimulator
- Where
- 3 sites in United States
- Volunteers
- 150 people
- Sponsor
- Salvia BioElectronics
Primary Headache Disorder
Feasibility of a Developmentally-tailored Mobile App for Tracking Mood and Pain in Children With Migraine
This study aims to inform the continued development of a mobile app intended to support the treatment of CYP with migraine. After extensive public and patient involvement, Happyr Health has developed a mobile app that allows…
- Trial name
- NCT05337930
- Testing
- Happyr App
- Where
- United Kingdom
- Sponsor
- Happyr Ltd
Migraine Disorders
A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2)
This is a randomized, double-blind, placebo-controlled, crossover, two-attack, out-patient, early-intervention evaluation of subjects who have migraine with or without aura and who discontinued use of short acting triptan(s)…
- Trial name
- NCT00383162
- Testing
- Combination Product (sumatriptan succinate / naproxen sodium)
- Where
- 26 sites in United States
- Volunteers
- 173 people
- Sponsor
- GlaxoSmithKline
Migraine Headaches
To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migrane Headaches
to demonstrate the superiority of Trexima (combination of sumatriptan as the succinate 85 mg and naproxen sodium 500 mg) versus placebo in the acute treatment of migraine to demonstrate the superiority of Trexima versus the…
- Trial name
- NCT00434083
- Testing
- sumatriptan, naproxen sodium
- Where
- 2 sites in United States
- Volunteers
- 1,200 people
- Sponsor
- POZEN
Migraine
Study to Evaluate the PK of BMS-927711 in Patient With Migraine During Acute Migraine and Non-migraine Condition
The purpose of this study is to evaluate the pharmacokinetics (PK) of BMS-927711 during migraine and non-migraine condition.
- Trial name
- NCT01445067
- Testing
- BMS-927711 (CGRP Antagonist)
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- Pfizer
Migraine
Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine
This study will evaluate the potential for a pharmacokinetic (PK) interaction and provide safety and tolerability information when ubrogepant and erenumab or ubrogepant and galcanezumab are co-administered.
- Trial name
- NCT04179474
- Testing
- Ubrogepant, Erenumab, Galcanezumab
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Allergan
Migraine
Observational Study to Assess Migraine Prediction Tool
This is a prospective, observational study. The participant will be required to approve his/her participation in the study by completing the electronic consent form.
- Trial name
- NCT05523310
- Testing
- Daily questionnaire
- Where
- 3 sites in United States
- Volunteers
- 200 people
- Sponsor
- Theranica